Skip to main content
Delfa

← All trials/NCT04417582

Unknown

Life Style Modification Medical and Surgical Management in Patients With Obesity

Evaluation of Life Style Modification Medical and Surgical Treatment Modalities in Patients With Obesity: An Observational Study

Lead sponsor

Marmara University

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

1

Estimated enrollment

1,000

Study population

Bariatric Surgery, Obesity / overweight

Eligibility highlights

•BMI 18-65

Primary endpoints

•Weight loss•Metabolic improvement

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04417582
Org study ID09.2019.948

Timeline

Milestones

Study start2020-01-01actual
Study first posted2020-06-04actual
Last update posted2020-06-04actual
Primary completion2023-12-01estimated
Study completion2025-12-01estimated

Assets

Investigational agents

Liraglutide

Who this study enrolls

Bariatric SurgeryObesity / overweight

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

obese patients refered to our tertiary center for obesity evaluation or treatment

Inclusion criteria

Body mass index over 30 kg/m2 age between 18-65 years

Exclusion criteria

active malignancy pregnancy during involvement period chronic inflamatuar diseases

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
1
Glycemic / diabetes
1
Cardiometabolic biomarkers
1

Weight & body composition

1 endpoint
Primary/protocol endpoint/low confidence

weight loss

Time frame:6 months interval

threshold achievement, improvement

Glycemic / diabetes

1 endpoint
Primary/protocol endpoint/low confidence

metabolic improvement

Time frame:6 months interval

change from baseline, improvement

Cardiometabolic biomarkers

1 endpoint
Primary/protocol endpoint/low confidence

metabolic improvement

Time frame:6 month

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.